Target intelligence / Profile preview

Alpha-Glucosidase & Pancreatic Alpha-Amylase

Molecular classification
Enzyme, Glycoside hydrolase, Hydrolase, Amylase
01

Overview

Alpha-glucosidase and pancreatic alpha-amylase are key digestive enzymes responsible for the breakdown of complex carbohydrates into glucose for absorption in the small intestine. Alpha-glucosidase acts on terminal, non-reducing alpha-1,4-linked residues in oligosaccharides, releasing free glucose, while pancreatic alpha-amylase acts primarily in the lumen to hydrolyze internal alpha-1,4 bonds, producing maltose and dextrins. Both are clinically relevant targets for the control of postprandial hyperglycemia in diabetes and are inhibited by drugs such as acarbose and miglitol to slow glucose absorption and blunt glycemic spikes. Deficiency of alpha-glucosidase (acid form) is implicated in Pompe disease, a lysosomal storage disorder.

Other names
Acid alpha-glucosidasemaltaseGAAlysosomal alpha-glucosidaseglucosidase alphaacidglucosidaseAMY2Aamylase alpha 2Apancreatic amylase
02

Mechanism of action

Competitive inhibition of the enzyme active site to reduce carbohydrate digestion and glucose absorption, thereby blunting postprandial blood glucose spikes

03

Biological functions

Hydrolysis of terminal, non-reducing alpha-1,4-linked glucose residues in oligosaccharides to release alpha-D-glucose; digestion and mobilization of glycogen and dietary carbohydratesHydrolysis of internal alpha-1,4 glycosidic bonds in starch, glycogen, and related polysaccharides, generating maltose and other oligosaccharides
04

Disease associations

Diabetes mellitus (major targets for glycemic control)Pompe disease (alpha-glucosidase deficiency specifically)Other metabolic and storage diseases
05

Safety considerations

Gastrointestinal side effects (flatulence, diarrhea, abdominal discomfort due to undigested carbohydrates in the colon)Risk of hypoglycemia is low unless combined with other hypoglycemic agentsFor enzyme deficiency/replacement (Pompe disease): Immunogenicity, hypersensitivity reactions
06

Interacting drugs

Acarbose

5 more in the full profile.

07

Biomarkers

Glycated hemoglobin (HbA1c), postprandial blood glucose levels (pharmacodynamic markers, not direct molecular biomarkers)Dried blood spot test for Pompe disease (in context of acid alpha-glucosidase deficiency)

Beyond the preview

Go deeper on Alpha-Glucosidase & Pancreatic Alpha-Amylase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-Glucosidase & Pancreatic Alpha-Amylase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call